UNSPSC 51295101: Beloxepin

This classification denotes an antidepressant agent with the molecular formula C19H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G905IN29U4, chemically known as ( -)-cis-1,3,4,13b-tetrahydro-2,10-dimethyldibenz(2,3:6,7)oxepino(4,5-c)pyridin-4a(2h)-ol but generally known as beloxepin, which bears US NIH Compound Identifier 166560. European Medicines Agency schedules Beloxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05689MIG.

UNSPSC 51295101 Beloxepin is a Commodity code that maps to state and local government procurement of naloxone, drug deactivation systems, and generic multi-source pharmaceuticals for public health, emergency response, and community health programs. The code captures purchasing of opioid-reversal medications, harm-reduction equipment, and over-the-counter pharmaceutical products distributed through state health departments, county health agencies, and cooperative purchasing alliances. Recent solicitations show state and local buyers procuring naloxone in significant volumes for community health initiatives and emergency preparedness, coupled with broader pharmaceutical acquisition programs serving multiple jurisdictions through centralized cooperative frameworks. Issuing bodies include county health departments, state health and human services commissions, and multistate purchasing alliances that aggregate demand across participating states and local governments.

Activity under the code appears concentrated in the Southeast and Upper Midwest, with documented recent procurement in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling exploratory procurement that will likely lead to formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness and 25 percent on compliance and capability factors including cGMP certification, Drug Supply Chain Security Act compliance, and EDI capability through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson.